April 30, 2020 / 12:25 PM / a month ago

BRIEF-Mesoblast - Phase 2/3 Randomized Controlled Trial Of Remestemcel-L In 300 Patients With COVID-19 Acute Respiratory Distress Syndrome Begins Enrollment

April 30 (Reuters) - Mesoblast Ltd:

* PHASE 2/3 RANDOMIZED CONTROLLED TRIAL OF REMESTEMCEL-L IN 300 PATIENTS WITH COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME BEGINS ENROLLMENT

* MESOBLAST - MORE THAN 20 MEDICAL CENTERS ACROSS UNITED STATES WILL PARTICIPATE IN TRIAL WHICH IS EXPECTED TO COMPLETE ENROLLMENT WITHIN 3-4 MONTHS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below